What is the treatment for Cannabinoid Hyperemesis Syndrome (CHS) in a chronic cannabis user?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 22, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment for Cannabinoid Hyperemesis Syndrome (CHS)

Complete and permanent cessation of cannabis use is the only definitive cure for CHS and must be the primary treatment goal. 1, 2

Acute Management in the Emergency Department

First-Line Pharmacologic Interventions

Haloperidol or droperidol should be your first-line antiemetic agents, as butyrophenones reduce hospital length of stay by nearly 50% (6.7 vs 13.9 hours, p=0.014) compared to conventional antiemetics. 2 These dopamine antagonists are consistently more effective than standard antiemetics like ondansetron, which often fails in CHS. 1, 3

Benzodiazepines (particularly lorazepam) are the most effective acute treatment for nausea and vomiting in CHS based on multiple prospective studies, addressing both the stress-mediated component and providing powerful sedation. 2, 4, 5

Topical capsaicin 0.1% cream applied to the abdomen activates TRPV1 receptors and provides consistent symptomatic relief as an adjunctive therapy. 1, 2 This mimics the mechanism of hot showers that patients compulsively use. 1

What NOT to Use

Never use opioids - they worsen nausea, carry high addiction risk, and do not address the underlying pathophysiology. 1, 2, 4 This is a critical pitfall to avoid.

Ondansetron may be tried but expect limited efficacy compared to its use in other conditions, as CHS does not reliably respond to conventional antiemetics. 1, 3

Supportive Care

Provide intravenous fluids for dehydration and correct electrolyte abnormalities. 6, 7 Hot showers or baths provide temporary relief and serve as a diagnostic clue (present in 44-71% of cases). 1, 2

Diagnostic Confirmation Before Treatment

Rule out life-threatening conditions first: acute abdomen, bowel obstruction, mesenteric ischemia, pancreatitis, and myocardial infarction. 1, 2 Once excluded, confirm CHS diagnosis requires all three criteria:

  • Cannabis use >1 year before symptom onset with frequency >4 times weekly 1, 2
  • Stereotypical episodic vomiting ≥3 episodes annually 1, 2
  • Complete symptom resolution after 6+ months of abstinence or duration equal to 3 typical vomiting cycles 1, 2

Long-Term Management and Prevention

Tricyclic antidepressants (amitriptyline) are the mainstay of long-term preventive therapy: start at 25 mg at bedtime and titrate weekly by 25 mg increments to reach the minimal effective dose of 75-100 mg. 1, 2, 4 This is the only medication with evidence for preventing recurrent episodes.

Cannabis cessation counseling is essential and non-negotiable - inform patients that complete resolution requires at least 6 months of continuous abstinence. 1, 2 This is both diagnostic and therapeutic.

Provide psychological support, as anxiety and depression are common comorbidities. 1, 4 Consider co-management with psychiatry for patients with extensive psychiatric comorbidity or treatment resistance. 1

Perioperative Considerations

For patients undergoing surgery, the American Gastroenterological Association and British Journal of Anaesthesia recommend enhanced multimodal antiemetic prophylaxis that differs from standard PONV protocols. 2 Anticipate higher anesthetic and analgesic requirements in chronic cannabis users. 2

Cannabis Withdrawal Syndrome Overlap

Be aware that 47% of regular cannabis users experience withdrawal symptoms (anxiety, irritability, insomnia, GI symptoms) within 24-72 hours of cessation, peaking at days 2-6. 4 This acute withdrawal phase lasts 1-2 weeks. 4 For patients with severe withdrawal consuming high amounts of cannabis, consider referral to addiction medicine specialists who can guide treatment with nabilone or nabiximols substitution. 4

Common Pitfalls

CHS is frequently underdiagnosed due to limited clinician awareness, leading to extensive unnecessary testing. 2, 3 Once CHS is suspected based on cannabis use pattern and hot water bathing behavior, focus on making an early diagnosis rather than pursuing exhaustive investigations. 4 The prevalence continues to rise with increasing cannabis potency and legalization. 3, 6

References

Guideline

Management of Cannabis Hyperemesis Syndrome (CHS)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Cannabinoid Hyperemesis Syndrome Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Cannabis Withdrawal Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review.

Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.